Teva wins US nod for Actavis after divestiture of 79 drugs
London
THE US Federal Trade Commission (FTC) has approved Teva Pharmaceutical Industries Ltd's US$40.5 billion purchase of Allergan Plc's generic drug-making unit after the companies agreed to the biggest divestiture ever in a pharmaceutical merger to preserve competition.
The companies agreed to sell 79 existing and future drugs including anaesthetics, antibiotics, weight-loss drugs and oral contraceptives to 11 rival firms to win approval, according to an FTC statement on Wednesday. The divestitures must be completed 10 days after Teva's acquisition of Allergan's generics unit Actavis Inc is complete, the commission said.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
HCA beats first-quarter profit estimates on higher patient admissions
US FDA approves Pfizer’s gene therapy for rare bleeding disorder
EU toughens rules on Chinese fashion retailer Shein
Best World under fire from shareholders at AGM over dividends, director salaries
‘Extreme’ climate blamed for world’s worst wine harvest in 62 years
Sheng Siong Q1 net profit up 9.3% on higher revenue